Clinical trials: Hospitalized COVID-19
Severe Pneumonia
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as…
- Trial name
- NCT04794803
- Testing
- Reparixin, Standard of care
- Where
- 4 sites in Brazil, Italy
- Volunteers
- 56 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID-19
The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Patients With Covid-19
The coronavirus disease 2019 (COVID-19) has spread rapidly and caused a global pandemic, as defined by the WHO, within a short period of time.
- Trial name
- LUSZ_SCORE (NCT05848427)
- Testing
- LUSZ P
- Where
- 2 sites in Lebanon
- Volunteers
- 1,000 people
- Sponsor
- Lebanese University
COVID-19 Severe Pneumonia, Acute Lung Injury
Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute…
- Conditions
- COVID-19 Severe Pneumonia, Acute Lung Injury, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- NCT04369469
- Testing
- Ravulizumab, BSC
- Where
- 39 sites in United States, France and 3 more
- Volunteers
- 202 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Asymptomatic COVID-19
Study of Oral High/Low-dose Cepharanthine Compared With Placebo in Non Hospitalized Adults With COVID-19
The purpose of this study is to evaluate the efficacy and safety of high/low-dose cepharanthine for the Treatment of COVID-19 in asymptomatic and non-pneumonia mild adult participants with COVID-19 who do not need to be in the…
- Trial name
- NCT05398705
- Testing
- Cepharanthine
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
COVID-19
A Phase 1/2 Study to Assess Safety and Efficacy of BAT2020 in Hospitalized COVID-19 Patients
This is a randomized study to assess safety, pharmacokinetics, immunogenicity, and efficacy of BAT2020 in hospitalized patients infected with COVID-19.
- Trial name
- NCT04432766
- Testing
- BAT2020
- Where
- United States
- Sponsor
- Bio-Thera Solutions
Psychiatric Disorder, Covid19
PSYCHIATRIC Disorders and Covid-19
Given the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with…
- Trial name
- PSYCHIC (NCT04358042)
- Testing
- Brief Psychiatric Rating Scale, Depression, Anxiety and Stress Scale, Impact of Event Scale-Revised
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Nantes University Hospital
Covid19
Vaccination for Recovered Inpatients With COVID-19 (VATICO)
In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial at selected sites who received certain pre-specified blinded investigational agents or placebo as part of that trial, and who have since achieved…
- Trial name
- NCT04969250
- Testing
- Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
- Where
- 30 sites in United States, Nigeria and 4 more
- Volunteers
- 66 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital…
- Trial name
- COROMEC (NCT04678193)
- Testing
- Coromec Registry with ECL-19
- Where
- 3 sites in United States, India and 1 more
- Volunteers
- 27,000 people, healthy volunteers welcome
- Sponsor
- Aventyn, Inc.
Covid-19
Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19
The 2019 coronavirus disease (Covid-19) is a new disease caused by the SARS-CoV2 virus of which many things are not yet known. Among others, there is a need to define the best therapeutic strategy to treat Covid-19, improving…
- Trial name
- NCT04420299
- Testing
- Bemiparin
- Where
- 2 sites in Spain
- Volunteers
- 81 people
- Sponsor
- Fundación de investigación HM
ARDS, COVID
Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique
COVID 19 is a novel and severe disease. One of the problems is that the virus disturbs the lungs and cause water accumulation in lungs alveolus (ARDS).
- Trial name
- NCT04406493
- Testing
- Lung impedance technique
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hillel Yaffe Medical Center
COVID, COVID-19
Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19
Studying the efficacy of IL-6 inhibition utilizing single or double dose subcutaneous administration of Sarilumab in patients with severe respiratory distress caused by COVID19 regarding improvement in oxygen demands and other…
- Conditions
- COVID, COVID-19, Corona Virus Infection
- Trial name
- NCT07196306
- Testing
- Sarilumab 200 MG/1.14 ML Subcutaneous Solution
- Where
- 3 sites in United States
- Sponsor
- BayCare Health System
COVID-19, Coronavirus Infection
Study to Evaluate the Effect of a Probiotic in COVID-19
A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients…
- Trial name
- NCT04390477
- Testing
- Probiotic
- Where
- 2 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Bioithas SL
COVID-19
A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia
Evaluate the safety and effect of ORTD-1 on COVID-19 related pneumonia.
- Trial name
- NCT04708236
- Testing
- ORTD-1 low dose, ORTD-1 mid dose, ORTD-1 high dose
- Where
- United States
- Sponsor
- Oryn Therapeutics, LLC
COVID-19
Prognosis of Geriatric Patients 1 Year After Hospitalization for COVID-19
Old patients hospitalized in Acute Geriatric Units are characterize by advanced age, frailty, high number of comorbidities, cognitive impairment and loss of functional autonomy.
- Trial name
- PROVID-Ger (NCT05261061)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients…
- Trial name
- NCT04628143
- Testing
- Nafamostat Mesilate
- Where
- South Korea
- Volunteers
- 13 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Covid19
Symprove (Probiotic) as an add-on to COVID-19 Management
The major impact of COVID-19 has been that the severity of respiratory symptoms require intensive hospital treatment. There is significant mortality and many of the survivors have a delayed recovery requiring intensive prolonged…
- Trial name
- NCT04877704
- Testing
- Symprove (probiotic)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- King's College Hospital NHS Trust
COVID-19
Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with…
- Trial name
- NCT05185284
- Testing
- Favipiravir, Remdesivir
- Where
- 6 sites in Russia
- Volunteers
- 217 people
- Sponsor
- Promomed, LLC
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Pulmonary Fibrosis, COVID-19 Pneumonia
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
- Conditions
- Pulmonary Fibrosis, COVID-19 Pneumonia, Long COVID
- Trial name
- NCT04948203
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Chicago
COVID-19
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized…
- Trial name
- NCT04464395
- Testing
- CPI-006, Standard of Care
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corvus Pharmaceuticals, Inc.